ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health Assessment Questionnaire (HAQ)"

  • Abstract Number: 1577 • ACR Convergence 2020

    Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

    Jeffrey Sarazin1, Ann Impens2, Nada Abdulaziz1, Stacey Anderson3, Leslie Fecher1, Christopher Lao1 and Elena Schiopu1, 1Michigan Medicine, Ann Arbor, MI, 2Midwestern University, Ann Arbor, IL, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
  • Abstract Number: 1736 • ACR Convergence 2020

    Health Assessment Questionnaire Predicts All-Cause Mortality at One Year in Patients with Early Rheumatoid Arthritis

    Safoora Fatima1, Orit Schieir2, Marie-France Valois3, Susan Bartlett3, Louis Bessette4, Gilles Boire5, Glen Hazlewood6, Carol Hitchon7, Edward C Keystone8, Diane Tin9, Carter Thorne9, Vivian Bykerk10, Janet Pope11 and Canadian Early Arthritis Cohort (CATCH) Investigators12, 1University of Western Ontario, London, ON, Canada, 2Canadian Early Arthritis Cohort Study, Montreal, Canada, 3McGill University, Montreal, Canada, 4Laval University, Quebec, Canada, 5Universite de Sherbrooke, Sherbrooke, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mount Sinai Hospital, Toronto, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10Hospital for Special Surgery, New York, NY, 11Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 12Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Patients with RA are at greater risk of mortality than the general population. Higher HAQ disability has been associated with hospitalizations and mortality in…
  • Abstract Number: 1880 • ACR Convergence 2020

    Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis

    Alexis Ogdie1, Mark Hwang2, Phani Veeranki3, Alexandria Portelli3, Steven Sison3, Jason Shafrin3, Sofia Pedro4, Esther Yi5 and Kaleb Michaud6, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 3PRECISIONheor, Los Angeles, 4FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita

    Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…
  • Abstract Number: 1891 • ACR Convergence 2020

    Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study

    Ashit Syngle1, Nidhi Garg2 and Kanchan Chauhan1, 1Healing Touch City Clinic, Chandigarh, Chandigarh, India, 2Chitkara University, Rajpura, Punjab, India

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…
  • Abstract Number: 1995 • ACR Convergence 2020

    Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study

    Sara Marsal1, Hector Corominas2, Juan Jose De Agustin De Oro3, Carolina Perez Garcia4, Maria Lopez Lasanta3, Helena Borrell3, Delia Reina5, Raimon Sanmartí6, Francisco Javier Narváez7, Clara Franco-Jarava8, Charles Peterfy9, Jose Antonio Narvaez10, Vivek Sharma11, Konstantinos Alataris11, Mark Genovese12 and Matthew Baker13, 1Hospital Universitari Vall d'Hebron, Barcelona, Spain, 2Institut Rec. Hospital de la Santa Creu I Sant Pau., Barcelona, Spain, 3Hospital Universitari Vall d’Hebron, Barcelona, Spain, 4Hospital Universitari Parc Salut Mar, Barcelona, Spain, 5Hospital Moises Broggi, Barcelona, Spain, 6Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, 7Hospital Bellvitge, BARCELONA, Spain, 81Hospital Universitari Vall d’Hebron, Barcelona, Spain, 9Spire Sciences, Inc., Boca Raton, FL, 10Clinica Diagonal, Barcelona, Spain, 11Vorso Corp, Redwood CIty, CA, 12Stanford University Medical Center, Palo Alto, CA, 13Stanford University, Menlo Park, CA

    Background/Purpose: Vagus nerve stimulation (VNS) has been shown to improve rheumatoid arthritis (RA) disease severity in patients with refractory disease (1,2). A multi-center pilot study…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology